Advanced acromegaly: successful disease control for more than 16 years using octreotide LA

Omayma Elshafie and Nicholas Woodhouse
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman

Summary
A 79-year-old male presented with a 10-year history of intermittent headache, sweating, persistent hand numbness and uncontrolled hypertension. He was receiving Nifedipine and Hydrochlorothiazide. On examination (O/E), his BP was 180/100 he was acromegalic. His growth hormone (GH) was 10 mIU/L (0.0–0.1) and his insulin-like growth factor (IGF-1): 952 µg/L (76–160). An MRI of the pituitary revealed a 3 × 2 cm pituitary macroadenoma. Surgery was refused and the family agreed for a therapeutic trial of octreotide. His GH levels fell immediately. Two weeks later he was switched to long-acting monthly octreotide in September 2003. During his 16-year follow-up, he has remained well and asymptomatic off medications for hypertension. His BP and IGF-1 levels were also normal until octreotide Long acting (LA) octrotide was stopped for 3 months at age 96. During this period the IGF-1 level returned to pretreatment levels 500 ng/L (50–141), GH 24 mIU/L (0.0–0.1), and a small residual tumour 0.5–0.8 cm was seen on the MRI. Octreotide LA was restarted and the IGF-1 and GH levels returned to normal. He continues the same treatment to date age 97 without side effects. We conclude that the successful control of IGF-1, GH levels, hypertension, tumour size and clinical symptoms for more than 16 years occurred using octreotide LA in an elderly advanced acromegalic patient. To the best of our knowledge, this is the first report of the successful use of octreotide LA for more than 16 years.

Learning points:
- The value of a therapeutic trial of octreotide to identify responders.
- Control of GH and IGF-1 secretion using octreotide LA.
- The report of the successful use of octreotide for more than 16 years irrespective of age.

Background
Acromegaly results from persistent hypersecretion of growth hormone (GH). Excess GH stimulates hepatic secretion of insulin-like growth factor-1 (IGF-1), which causes most of the clinical manifestations of acromegaly.

The clinical diagnosis is often delayed because of the slow progression of the signs of acromegaly over a period of many years.

Acromegaly is almost always caused by a somatotroph (growth hormone (GH)-secreting) adenoma of the pituitary gland and is associated with increased morbidity and mortality. As a result, almost all patients should be treated, even those who are asymptomatic and those in whom the disorder does not seem to be progressing. One exception is a patient with a short life expectancy who is not expected to live long enough to benefit from therapy (1, 2).

In this paper, we report the successful control of IGF-1 levels, hypertension, tumour size and clinical symptoms for more than 16 years using Octreotide LA in elderly advanced acromegalic patient age 96 without side effects.
Case presentation

A 79-year-old male presented with a 10-year history of intermittent headache, sweating, persistent hand numbness and uncontrolled hypertension. Carpel tunnel decompression surgery had been carried out earlier. He was receiving Nifedipine 40 mg bd and Hydrochlorothizide 25 mg od. O/E, His BP was 180/100, clinically he was acromegalic. He was referred to our hospital for further management.

Investigation

Investigations on admission showed GH 10 mIU/L (0.0–0.1), and IGF-1: 952 µg/L (76–160). Other pituitary hormones were normal. Skull X-rays showed ballooning of the pituitary fossa (Fig. 1A). An MRI of the pituitary revealed a 3 × 2 cm pituitary macroadenoma (Fig. 1B). US abdomen showed no gall stones.

Surgery was refused and the family agreed to a therapeutic trial of Octreotide 100 mcg sc three times daily for 1 week. His GH decreased immediately the following day (Fig. 2).

Treatment

After 2 weeks he was switched to long-acting monthly octreotide 40 mg on September 2003. He remained well, and asymptomatic off medications for hypertension. During his 16-year follow-up, he remained well and asymptomatic with a normal BP. Other pituitary hormones remained normal before and after treatment. A colonoscopy was done three times and no polyps were identified. IGF-1 levels were also normal until octreotide LA was stopped for 3 months’ age 96. During this period the IGF-1 level returned to pretreatment levels 500 ng/L (50–141) and GH 24 mIU/L (0.0–0.1) (Fig. 3). Small residual tumour 0.5–0.8 cm was seen on the MRI (Fig. 4).Octreotide LA 40 mg was restarted and the IGF-1 and GH levels returned to normal. He continues the same treatment up to now at age 97 years without side effects.

Outcome and follow-up

The patient’s symptoms; uncontrolled hypertension and elevated GH and IGF-1 levels disappeared throughout his medical treatment. His BP did not require any medications for 16 years until octreotide was stopped for 3 months, after which he became symptomatic, his BP increased and GH and IGF-1 were both elevated. He returned to normal after he was restarted on octreotide LA.

Discussion

Acromegaly is almost always caused by a somatotroph (growth hormone (GH)-secreting) adenoma of the pituitary gland and is associated with increased morbidity and mortality. As a result, almost all patients should be treated, even those who are asymptomatic and those in whom the disorder does not seem to be
Transsphenoidal surgery is the usual initial therapy. This includes patients with a microadenoma, a macroadenoma that appears to be fully resectable, or a macroadenoma causing impairment of vision. Surgery should be performed by a neurosurgeon with considerable experience in pituitary surgery (2).

This patient was symptomatic with intermittent headache, sweating, persistent hand numbness and uncontrolled hypertension. The MRI confirmed a 3 × 2 cm macroadenoma. He refused surgery. On octreotide LA 40 mg monthly (3, 4) there were no side effects (5). Interestingly all his symptoms disappeared and BP normalized without medications. Octreotide has a significant antineoplastic effect on somatotroph adenomas (6) and his tumour disappeared after 2 years (7).

The goals of therapy in patients with acromegaly are to lower the serum insulin-like growth factor-1 (IGF-1) concentration to within the normal range for the patient's age and gender, control adenoma size, reduce mass effects, improve symptoms and reverse metabolic abnormalities such as diabetes mellitus and hypertension. Our patient remained well and maintained a normal GH, IGF-1, BP and was asymptomatic for 16 years on octreotide LA 40 mg monthly IM injections (3, 8).

Octreotide was stopped for 3 months, hoping he been cured. However, his symptoms recurred and IGF-1 increased to 500 and GH to 24. The MRI showed 0.5–0.8 cm microadenoma. He was restarted on Octreotide LA 40 mg monthly and the IGF-1 and GH normalized.

Reports of using octreotide beyond 9 years are not available (9), our patient is substantially older than other reported cases (10).

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
O Elshafie and N Woodhouse

Long term octreotide in acromegaly

DOI: 10.1530/EDM-20-0102

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent
Written patient consent was obtained from the patient’s mother for publication of this case report.

Author contribution statement
O Elshafie and N Woodhouse were responsible for the diagnosis and management of the patient throughout and preparation of the manuscript.

References
1 Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 3189–3202. (https://doi.org/10.1172/JCI39375)
2 Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102–152. (https://doi.org/10.1210/er.2002-0022)
3 Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397–1403.
4 Giustina A, Mazzotti G, Cannavò S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. Journal of Clinical Endocrinology and Metabolism 2017 102 2454–2464. (https://doi.org/10.1210/jc.2017-00142)
5 Grasso LF, Aurieremma RS, Pivonello R & Colao A. Adverse events associated with somatostatin analogs in acromegaly. Expert Opinion on Drug Safety 2015 14 1213–1226.
6 Thapar K, Kovacs KT, Stefaneseau L, Schetthauer BW, Horvath E, Lloyd RV, Li J & Laws ER. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clinic Proceedings 1997 72 893–900. (https://doi.org/10.1016/S0025-6196(11)63538-2)
7 Colao A, Pivonello R, Aurieremma RS, Briganti E, Galdiero M, Tortora F, Caraci E, Cirillo S & Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2112–2118. (https://doi.org/10.1210/jc.2005-2110)
8 Melmed S. New therapeutic agents for acromegaly. Nature Reviews: Endocrinology 2016 12 90–98. (https://doi.org/10.1038/nrendo.2015.196)
9 Espinosa-de-los-Monteros A, Gonzalez B, Vargas G, Sosa E & Mercado M. Octreotide LAR treatment of acromegaly in ‘real life’: long-term outcome at a tertiary care center. Pituitary 2015 18 290–296. (https://doi.org/10.1007/s11102-014-0570-0)
10 Ceccato F, Barbot M, Lizzul L, Cuccarollo A, Selmini E, Merante Boschin I, Daniele A, Saller A, Occhi G, Regazzo D, et al. Clinical presentation and management of acromegaly in elderly patients. Hormones 2020. (https://doi.org/10.1007/s42000-020-00235-5)

Received in final form 6 October 2020
Accepted 30 October 2020

https://edm.bioscientifica.com/